Hema Now
In this episode of Hema Now, we sit down with internationally recognised myeloma expert Ola Landgren. He shares his career journey, the vision behind establishing the Myeloma Research Institute, and how its unique scientific ecosystem is advancing research and patient care. We explore the future of multiple myeloma, from investigator-initiated clinical trials and AI to early disease detection, treatment-resistant disease, and the potential to intervene before myeloma becomes clinically active.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Ola Landgren is Chief of the Division of Myeloma at Sylvester Comprehensive Cancer Center, Miami, Florida, and Professor of Medicine at the University of Miami Miller School of Medicine, Florida, USA. He is an internationally recognised expert in multiple myeloma, with a research programme focused on the biology, prevention, and treatment of the disease. His work spans early detection and intervention, clinical trials, and translational research, with a focus on advancing understanding and improving outcomes for people living with myeloma.
Timestamps:
00:00 – Introduction
00:45 – Career journey and turning point
04:00 – Establishing the myeloma institute
06:40 – Institute evolution and impact
09:48 – Current research and initiatives
13:56 – AI transforming myeloma research
17:30 – Early detection and intervention
22:01 – Improving outcomes and quality
24:43 – Understanding and raising awareness
26:28 – Three wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: AI, AI in healthcare, cancer prevention, cancer research, clinical trials, early detection, haematology, multiple myeloma, myeloma research, Myeloma Research Institute, oncology, precision medicine, relapsed myeloma, Sylvester Comprehensive Cancer Center, translational research.
